Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  Disease Landscape and Forecast Insights

Antibody-Drug Conjugates | Special Topics | Trends and Market Dynamics – Multi-indication | G7 | 2022

Login to access report north_east
Contact sales account_box

Antibody-drug conjugates have demonstrated their efficacy in the treatment of a broad range of tumor types, establishing the drug class as a versatile weapon against cancer. The approval of antibody-drug conjugates continues to transform the treatment paradigm for many oncology indications at an incredible rate. This Special Topics report provides a comprehensive market forecast of current and emerging antibody-drug conjugates and analyzes the market trends and dynamics in a range of oncology indications.

QUESTIONS ANSWERED

  • What is the timeline and current landscape for approved antibody-drug conjugates? What are the trends in each key oncology indication?
  • How will emerging antibody-drug conjugates be positioned in the market? How will the indication-specific market trends and dynamics evolve?
  • What is the commercial potential of current and emerging antibody-drug conjugates by brand, indication, combination type, and geography? How will the market evolve over the 2021-2031 forecast period?

GEOGRAPHIES

United States, EU5, Japan.

EPIDEMIOLOGY

Drug-treated patient populations by brand, indication, combination type, and geography for indications for which antibody-drug conjugates are approved or forecast for approval.

FORECAST

10-year, annualized, drug-level sales of antibody-drug conjugates through 2031, segmented by indication, combination type, and geography.

KEY DRUGS COVERED

Currently approved agents targeting HER2, TROP-2 and CD79b.

EMERGING THERAPIES

Phase III

PRODUCT DESCRIPTION

Clarivate’s Special Topics reports assess key trends in dynamic disease areas. This report offers a comprehensive market forecast of the antibody-drug conjugate landscape in relevant oncology indications.

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Biosimilars – Forecast – Oncology
In 2023, sales of branded MAb biologics in oncology exceeded $47 billion in the major pharmaceutical markets (United States, EU5, and Japan), and sales of biosimilars totaled approximately $5.5…
north_east
Report
Biomarkers in Oncology – Access & Reimbursement – Access & Reimbursement – Biomarker-Driven Prescribing in NSCLC, Colorectal Cancer, Malignant Melanoma (US)
Biomarker-driven prescribing is vital in the treatment of key oncology indications, particularly non-small-cell lung cancer (NSCLC), colorectal cancer, and malignant melanoma. Treatment of these…
north_east
Report
Dry and Wet Age-Related Macular Degeneration | Special Topics | US | 2019
The development of biosimilar versions of Lucentis and Eylea is of high interest in the ophthalmology market given the high cost of these agents, the large patient population suffering from retinal…
north_east
Report
Postoperative Pain | Special Topics | US | 2020
Postoperative pain comprises one of the larger segments of the total market for acute pain therapies, and it has experienced substantial growth over the past decade due to the market uptake of…
north_east
Report
Immune Checkpoint Inhibitors – Special Topics – Special Topics: Trends and Market Dynamics
Immune checkpoint inhibitors have transformed many oncology settings since their entry into the marketplace just over a decade ago. They are continuing to advance into earlier lines of therapy,…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east